A5055963015- Neurotransmitter Receptor Influence on Behavior
- Neuroscience and Neuropharmacology Research
- Migraine and Headache Studies
- Hair Growth and Disorders
- Receptor Mechanisms and Signaling
- Autoimmune Bullous Skin Diseases
- Pain Mechanisms and Treatments
- Psychosomatic Disorders and Their Treatments
- Genetics and Neurodevelopmental Disorders
- Restraint-Related Deaths
- Dupuytren's Contracture and Treatments
- Vestibular and auditory disorders
- Trigeminal Neuralgia and Treatments
- Suicide and Self-Harm Studies
- Chronic Myeloid Leukemia Treatments
- Sympathectomy and Hyperhidrosis Treatments
- CAR-T cell therapy research
- Attention Deficit Hyperactivity Disorder
- Zebrafish Biomedical Research Applications
- Eosinophilic Disorders and Syndromes
- Olfactory and Sensory Function Studies
- Body Image and Dysmorphia Studies
- Biochemical effects in animals
- Statistical Methods in Clinical Trials
- Ophthalmology and Eye Disorders
Eli Lilly (United States)
2019-2025
John Wiley & Sons (United States)
2023
Hudson Institute
2023
University of Minnesota
2014-2016
Harvard University
2014
McLean Hospital
2014
University of Michigan
2007-2013
Michigan United
2012
National Institute on Drug Abuse
2002-2004
Significance The recent rise in opioid addiction has made development of new treatments a public health priority. effort been impeded by distinct lack understanding how opioid-induced alterations synaptic transmission and cellular plasticity within reward brain regions, such as the nucleus accumbens (NAc), drive behavior. We examined whether repeated morphine induces differential strength subpopulations NAc neurons, those expressing dopamine D1 or D2 receptors, that play opposing roles...
Abstract Repeated exposure to psychostimulant drugs produces long‐lasting changes in dendritic structure, presumably reflecting a reorganization patterns of synaptic connectivity, brain regions that mediate the psychomotor activating and incentive motivational effects these drugs, including nucleus accumbens prefrontal cortex. However, repeated also facilitates transition control some behaviors from action–outcome associations behavior controlled by stimulus–response (S–R) habits. This...
Introduction Acute medication overuse is prevalent in patients with migraine. Methods In three phase 3, double-blind, randomized, placebo-controlled studies, episodic migraine (EVOLVE-1 and EVOLVE-2) or chronic (REGAIN) were randomized 2:1:1 to monthly subcutaneous injections of placebo galcanezumab 120 240 mg for 3 6 months. This subgroup analysis evaluated mean changes the number headache days each treatment among versus without baseline acute via mixing modelling repeated measures....
Abstract Objective To evaluate changes in interictal burden with galcanezumab versus placebo patients episodic (EM) or chronic migraine (CM). Background The disruptive effects of occur both during attacks (ictal period) and between (interictal period), affecting work, school, family, social life. Migraine clinical trials typically assess ictal endpoints, neglecting burden. Methods CONQUER was a 3‐month, double‐blind study that randomized adult EM CM who had experienced failure two to four...
Introduction: Baricitinib, a approved for adults with severe alopecia areata (AA), demonstrated high level of sustained efficacy (89.1%) at Week 152 among patients who achieved Severity Alopecia Tool (SALT) score ≤20 52 following one year treatment once-daily baricitinib 4 mg in phase 3 trials (BRAVE-AA1, BRAVE-AA2). In this post hoc analysis, we characterize patterns loss response during maintenance (Weeks 52–152) the 10.9% (n=14) (SALT >20) and explore differences between lost vs...
Introduction: Previous data on baricitinib treatment in severe alopecia areata (AA) has shown that response varies by baseline disease severity and duration of current episode. In general, hair regrowth varies, clinicians lack how long to optimally treat patients achieve response. the literature, time onset improvement (defined as 30% from SALT score, i.e. SALT30 can predict ultimate achievement score ≤20 Week 52. this analysis, we evaluated improvement(SALT30) meaningful response(SALT ≤20),...
Background The repeated administration of psychostimulant drugs produces a persistent and long-lasting increase ("sensitization") in their psychomotor effects, which is thought to be due changes the neural circuitry that mediate these behaviors. One index neuronal activation used identify brain regions altered by exposure involves ability induce immediate early genes, such as c-fos. Numerous reports have demonstrated past drug experience alters c-fos striatum, but very few examined Fos...
Abstract Neuroadaptations induced by high‐dose cocaine treatment have been hypothesized to persist after the cessation of drug and mediate expression sensitization tolerance cocaine. We looked for evidence these neuroadaptations in rats receiving more modest behaviorally effective treatments. Rats were exposed either a sensitizing regimen seven once‐daily injections 15 mg/kg or tolerance‐producing involving continuous infusion same daily dose. assessed enzyme activity levels protein kinase A...
Abstract Background Patients with episodic migraine (EM) a higher-frequency of headache days (HFEM: 8–14 days/month) have greater disease burden and higher risk progressing to chronic (CM) associated acute treatment overuse versus those low-frequency EM (LFEM: 4–7 days/month). In this post hoc analysis, we assessed the proportions patients who shifted from HFEM LFEM very (VLFEM: 0–3 status following galcanezumab placebo. Methods EVOLVE-1 EVOLVE-2 were double-blind, Phase 3 studies in EM....
Acute cocaine can inhibit catecholamine biosynthesis by regulating the enzymatic activity of tyrosine hydroxylase via alterations in phosphorylation state enzyme. The mechanisms underlying acute cocaine-dependent regulation have not been determined. In this study, 0, 15 or 30 mg/kg was administered intraperitoneally to rats and brain examined using antibodies specific for phosphorylated forms serine-19, -31 -40 hydroxylase. caudate nucleus accumbens, dose-dependently decreased levels -40....
Abstract Background The Severity of Alopecia Tool (SALT) is a standardized method for quantifying scalp hair loss in alopecia areata (AA). SALT scores can be used to guide treatment decisions and are widely as eligibility criteria endpoints clinical trials AA. However, clinicians may unfamiliar with assessing envisioning practice. Objectives To aid the determination application setting, this manuscript seeks contextualize using patient images from trial adults severe Methods Images 722...
Objective: Evaluate changes in measures of depression and anxiety after 3 months galcanezumab treatment patients with prior migraine preventive failures. Background: While are well-described comorbidities, little is known about the effects prevention on these comorbidities. Design/Methods: Adults episodic or chronic multiple failures received 3-month 120mg/month (n=232) placebo (n=230). Patients rated symptoms severity using Patient Health Questionnaire-9 (PHQ-9) 7-item Generalized Anxiety...
Introduction: In pivotal BRAVE-AA1 and AA2 phase 3 clinical trials, the Janus kinase (JAK)1/JAK2 inhibitor baricitinib has demonstrated efficacy in achieving clinically meaningful regrowth of hair patients with severe alopecia areata. While a significant proportion achieve by weeks 36 52 on versus placebo, other patients, particularly those longer episode duration or higher disease severity, require more time therapy to see full treatment benefit. The benefit distribution SALT scores at Week...